Amlodipine in the current management of hypertension
The Journal of Clinical Hypertension · 2023-09 · 25 (9) · 801-807
DOI: 10.1111/jch.14709 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Hypertension, online erschienen am 07.08.2023. Verfasst von Ji-Guang Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Amlodipine, Hypertension. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Hypertension is the leading cause of death worldwide, affecting 1.4 billion people. Treatment options include the widely used calcium channel blockers, among which amlodipine, a dihydropyridine, has unique characteristics that distinguish it from other drugs within this class. This review aims to provide an updated overview of the evidence supporting the use of amlodipine over the past 30 years and highlights its cardiovascular benefits in current hypertension management. Amlodipine has low renal clearance (7 mL/min/mg) and long half‐life (35–50 h) and duration of action, which allows it to sustain its anti‐hypertensive effect for more than 24 h following a single dose. Additionally, blood pressure (BP) control is maintained even when a dose has been missed, providing continuous protection in case of incidental noncompliance. It has proven to reduce BP variability and successfully lower BP. Amlodipine also controls BP in patients with a systolic/diastolic BP of 130/80 mm Hg or higher, diabetes, or chronic kidney disease without worsening glycemic or kidney function. Additionally, amlodipine is a wise choice for older adults due to its ability to control BP and protect against stroke and myocardial infarction. Side effects of amlodipine include edema, palpitations, dizziness, and flushing, which are more common with the higher dose of 10 mg. Amlodipine is cost effective and predicted to be cost saving when compared with usual care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Pharmacotherapy & Translational Research, University of Florida College of Pharmacy, Gainesville, Florida, USA.
- National Heart and Lung Institute, Imperial College London, London, UK.
ORCID-Profile: Ji-Guang Wang
Zitieren
APA
Wang, J. G., Palmer, B. F., Vogel Anderson, K., & Sever, P. (2023). Amlodipine in the current management of hypertension. The Journal of Clinical Hypertension, 25(9), 801-807. https://doi.org/10.1111/jch.14709
Vancouver
Wang JG, Palmer BF, Vogel Anderson K, Sever P. Amlodipine in the current management of hypertension. The Journal of Clinical Hypertension. 2023;25(9):801-807. doi:10.1111/jch.14709
BibTeX
@article{Wang2023,
author = {Wang, Ji-Guang and Palmer, Biff F and Vogel Anderson, Katherine and Sever, Peter},
title = {Amlodipine in the current management of hypertension},
journal = {The Journal of Clinical Hypertension},
year = {2023},
volume = {25},
number = {9},
pages = {801--807},
doi = {10.1111/jch.14709}
}
EUVIMED